Ateş KARATEKE, Zehra Nihal DOLGUN, Cihan İNAN, Cihan KARADAĞ, Cem İYİBOZKURT, Ahmet Salih ALTINTAŞ, Canan KABACA

The Use of Human Epididymis 4 and Cancer Antigen 125 Tumor Markers in the Benign or Malignant Differential Diagnosis of Pelvic or Adnexal Masses

Background: Ovarian cancer is one of the highestmortality cancers in gynaecology. Discrimination ofbenign masses from malignant ones may sometimesbecome a challenge for the clinician since there is not areliable tumour marker, thus some unnecessary, highlymorbid operations can be performed.Aims: To explore the efficacy of human epididymis4 (HE 4) and cancer antigen 125 (CA 125) markers indifferentiating malignant and benign pelvic masses ofovarian origin and to identify the cut-off points for thosemarkers.Study Design: Prospective study.Methods: Fifty-one patients who were diagnosed andplanned to undergo surgery for ovarian mass betweenJune 2008 and December 2008 were enrolled into thisstudy. Preoperative venous blood samples were takenand frozen for marker investigation and final diagnoseswere concluded by histopathological examination. Afterrecruitment of all cases CA 125 and HE 4 levels wereevaluated.Results: The statistical analysis did not indicate anystatistically significant difference between the CA 125levels of the patients with malignant and benign adnexalmasses (p=0.105). The HE 4 levels of the patients withmalignant adnexal masses were higher at a statisticallysignificant level compared to the patients with benignadnexal masses (p=0.002). For HE 4 tumour marker and atthe cut-off point of >25 pM, sensitivity was 1, specificity0.40, positive cut-off value 0.19, negative cut-off value 1,accuracy 0.47 and positive likelihood ratio 1.65.Conclusion: Human epididymis 4 is a better diagnostictool than CA 125 in benign-malignant discriminationof adnexal masses. The cut-off value of 25 pmol/L forhuman epididymis 4 will contribute to providing properguidance to patients with adnexal masses and applyingthe proper treatment method.

PDF

___

1. Al-Shukri M, Mathew M, Al-Ghafri W, Al-Kalbani M, Al-Kharusi L, Gowri V. A clinicopathological study of women with adnexal masses presenting with acute symptoms. Ann Med Health Sci Res 2014;4:286-8.
2. BerekJS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2015;131(Suppl 2):111-22.
3. Bankhead CR, Kehoe ST, Austoker J. Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG 2005;112:857-65.
4. Lataifeh I, Marsden DE, Robertson G, Gebski V, Hacker NF. Presenting symptoms of epithelial ovarian cancer. Aust N Z J Obstet Gynaecol 2005;45:211-4.
5. Kabaca C, Dolgun ZN, Telci A, Karateke A. Serum human epididymis protein 4 (HE 4) in the differential diagnosis of peritoneal tuberculosis: A report of two cases. Balkan Med J 2014;31:270-1.
6. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700.
7. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:2295-303.
8. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005;23:7919-26.
9. Fujiwara HI, Suzuki M, Takeshima N, Takizawa K, Kimura E, Nakanishi T, et al. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. Tumour Biol 2015;36:1045- 53.
10. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7.
11. Tuxen MK. Tumor marker CA 125 in ovarian cancer. J Tumor Markers Oncol 2001;16:49-68.
12. Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 2008;18:414-20.
13. Skates SJ, Xu FJ, Yu YH, Sjövall K, Einhorn N, Chang Y, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995;76(10 Suppl):2004-10.
14. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006;7:167-74.
15. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA 125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6.
16. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402-8.
17. Piovano E, Attamante L, Macchi C, Cavallero C, Romagnolo C, Maggino T, et al. The role of HE4 in ovarian cancer follow-up: a review. Int J Gynecol Cancer 2014;24:1359-65.
18. Chung SH, Lee SY, Ju W, Kim SC. Clinical efficacy of serum human epididymis protein 4 as a diagnostic biomarker of ovarian cancer: A pilot study. Obstet Gynecol Sci 2013;56:234-41.
19. Michalak M, Gąsiorowska E, Markwitz EN. Diagnostic value of CA 125, HE4, ROMA and logistic regression model in pelvic mass diagnostics - our experience. Ginekol Pol 2015;86:256-61.